Search PubMedSearch

Biomedical subjects

T Narukawa

Publications and source records attributed to T Narukawa.

3 recordsLinked to original sources

Fetal cells in the maternal circulation: detection of Y-sequence by gene amplification.

Detection of a Y-specific sequence in the maternal circulation has clinical importance because it would be useful in determining fetal gender in mothers with severe X-linked disorders. The method described in this paper has the advantage of requiring only small amounts of maternal blood. Numerous attempts have been made to identify XY cells in the blood of mothers bearing male fetuses; however, the results have been controversial. In this study, a member of the DYZ1 family and the XY homologous region of the amelogenin gene were used as targets for polymerase chain reaction detection of the Y chromosome. The subjects in this study were a group of 100 pregnant women at 17-20 weeks' gestation and 30 puerperal women who had given birth 2-5 days previously. All of the former underwent amniocentesis, with venous blood samples drawn before the procedure. Forty-five fetuses were confirmed as male by karyotyping amniocytes, and 30 of these were positive for the Y sequence in the DYZ1 region (sensitivity 66.7%). However, ten of the 55 cases diagnosed as female were also positive, giving a specificity of only 81.8%. Thus, the positive and negative predictive values were each 75%. In the amelogenin gene study, a positive Y signal was not detected in any of the cases examined. This study demonstrates the usefulness of polymerase chain reaction detection of Y-specific sequences in the maternal circulation. However, further investigation is necessary to increase the reliability for clinical application, because the method does produce false-positive results.

Base Sequence

Teratogenesis of dexamethasone and preventive effect of vitamin B12.

Ddy mice which were treated with 0.32 mg of dexamethasone were used. Vitamin B12 was injected subcutaneously into the animals from the 10th day to the 13th day with a dosage of 0.1r, 1r, or 10r. The rate of incidence of cleft palate was decreased to 77.0% in the 0.1r group, 58.1% in the 1r group and 67.9% in the 10r group as compared to the control value of 88.5%.

Animals